Poging GOUD - Vrij
Deadly Silence: India's Negligent Pharma Manufacturing Units
Bio Spectrum
|August 2025
Indian pharma manufacturing units are a ticking time bomb. Inflammable chemicals that require special handling are often callously used by ignorant workers leading to reactions, reactor blasts and deaths. Above it, ill-designed setups and less knowledge of hardware and software are taking a toll on the industry. Showing a lackadaisical attitude towards the way manufacturing sites are being operated, Indian pharma companies are at the receiving end of various domestic and global regulators. Overlooking safety issues will lead to more catastrophic events.
-
India's growing pharma industry has a sordid tale to say. Amidst the hype of 'Pharmacy of the World,' discussions about tariffs and patent expiry leading to an opportunity for Indian pharma companies, hardly any discussions are held on the killer pharma manufacturing facilities. Unless and until something fatal happens.
A majority of the pharma companies seem to turn a blind eye to the lurking danger at its manufacturing sites across the country. So much so that lives are lost due to these catastrophic events.
Pharma manufacturing plants store chemicals, sometimes inflammable that are always at high risk. Reports of manufacturing plants not complying with safety standards are nothing new. Not following safety and other protocols becomes a free ride for the US FDA to issue warning letters. The US watchdog is notoriously known for issuing warning letters and somewhere the feeling comes that the agency does it right on certain occasions.
The Indian pharma industry has a history of incidents leading to deaths at manufacturing facilities with fire breakouts the common one.
Multiple incidents
The industry is marred with fire safety issues. Reports of fatality in pharma plants due to fire, inhaling toxic gas etc. happen quite often.
The recent blast at the Sigachi Industries plant at Pashamylaram in Telangana points out a disaster that is being compared with the Bhopal Gas Tragedy that happened way back in 1984. The powerful blast led to more than 40 dead and scores injured.
The management of Sigachi Industries was booked for culpable homicide. A criminal investigation is being pursued where there are allegations of gross negligence by the company. It is also being claimed that repeated warnings of outdated and unsafe machinery were ignored.
Dit verhaal komt uit de August 2025-editie van Bio Spectrum.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Bio Spectrum
Bio Spectrum
Biotium's new cell barcoding kit streamlines flow cytometry with single-tube multiplexing
Biotium, a leading provider of fluorescent reagents and kits for life science research, has announced the release of the ViaPlex 2-Color Cell Barcoding Kit.
1 min
May 2026
Bio Spectrum
NATHEALTH names Dr Sangita Reddy as new President
NATHEALTH, an apex body representing the Indian healthcare industry, has announced Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group, as its new President for FY 2026-2027.
1 min
May 2026
Bio Spectrum
Rs 4.51 Lakh Crore Health Push: How State Budgets Are Powering India's Next Healthcare Leap
In recent years, state health budgets have transformed from simple financial documents into strategic instruments for improving healthcare outcomes.
7 mins
May 2026
Bio Spectrum
WHO lays focus on simulation exercises to strengthen health emergency readiness
To support countries to prepare more systematically against emergencies, WHO has recently released new global guidance which enables countries to move beyond oneoff emergency drills and establish National Health Simulation Exercise Programmes (NHSEP).
1 min
May 2026
Bio Spectrum
Akrivia Biosciences decodes breast cancer genomic heterogeneity
Akrivia Biosciences, a cancer genomics startup based in London and Mumbai, has announced a foundational scientific breakthrough that uncovers hidden organisation of cancer genomes, successfully decoding breast cancer genomic heterogeneity, a major bottleneck that has historically hindered the comprehensive understanding of tumour biology in patients.
1 min
May 2026
Bio Spectrum
Integrating AI for Tech-driven Ayurveda
A promising trend emerging in 2026 is the integration of artificial intelligence (AI) into ayurveda, to not only make ayurveda more accessible and scalable but to also create opportunities to back up ayurveda with science and technology.
2 mins
May 2026
Bio Spectrum
ASPIRE BIONEST signs MoU with Indian Immunologicals to advance One Health Innovation
ASPIRE BIONEST, a life sciences incubation centre at the University of Hyderabad, has signed a strategic Memorandum of Understanding (MoU) with Indian Immunologicals Ltd. (IIL), a leading vaccine-focused biotechnology company, to advance innovation under the One Health framework.
1 min
May 2026
Bio Spectrum
MSD India and Smile Foundation award 50 scholarships to aspiring pharmacy students
MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) in India has announced the awarding of scholarships to 50 students under its corporate social responsibility initiative 'Scholarship for Daughters' programme, a merit-based initiative aimed at supporting young women from underserved communities to pursue a Bachelor of Pharmacy degree at select accredited pharmacy colleges across India.
1 min
May 2026
Bio Spectrum
Thermo Fisher launches integrated platform to accelerate biologics development
Thermo Fisher Scientific Inc. has announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability.
1 min
May 2026
Bio Spectrum
Eurofins Viracor unveils ExPECT anti-CD19 (obe-cel) CAR T-cell assay
Eurofins Viracor, a leader in advanced clinical diagnostics, has announced the launch of the ExPECT anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor CAR T-cell therapy performance with validated precision and a quick turn-around-time for results.
1 min
May 2026
Listen
Translate
Change font size

